根据国家统计局数据显示：2025年12月中国中空玻璃产量为0.1亿平方米，同比下降0.9%；2025年1-12 月中国中空玻璃累计产量为1.3亿平方米，累计下降8.1%。 2020-2025年中国中空玻璃产量统计图 上市企业：旗滨集团（601636）,南玻Ａ（000012）,福耀玻璃（600660）,金晶科技（600586）,凯盛新能 （600876）,耀皮玻璃（600819）,山东药玻（600529）,亚玛顿（002623） 相关报告：智研咨询发布的《2026-2032年中国中空玻璃行业市场动态分析及发展趋势研判报告》 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

上市企业：旗滨集团（601636）,南玻Ａ（000012）,金晶科技（600586）,凯盛新能（600876）,耀皮玻璃 （600819）,山东药玻（600529）,亚玛顿（002623）,福耀玻璃（600660） 相关报告：智研咨询发布的《2026-2032年中国平板玻璃行业市场供需态势及前景战略研判报告》 根据国家统计局数据显示：2025年12月中国平板玻璃产量为8829万重量箱，同比增长3.4%；2025年1-12 月中国平板玻璃累计产量为97591万重量箱，累计下降3%。 2020-2025年中国平板玻璃产量统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

2020-2025年中国夹层玻璃产量统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：旗滨集团（601636）,南玻Ａ（000012）,福耀玻璃（600660）,金晶科技（600586）,凯盛新能 （600876）,耀皮玻璃（600819）,山东药玻（600529）,亚玛顿（002623） 相关报告：智研咨询发布的《2026-2032年中国夹层玻璃行业市场现状调查及发展趋向研判报告》 根据国家统计局数据显示：2025年12月中国夹层玻璃产量为1556万平方米，同比下降7.1%；2025年1-12 月中国夹层玻璃累计产量为16422.8万平方米，累计增长2.7%。 ...

1月13日，寒风阵阵。山东药玻（600529）发布的一则公告却"打破"了冬季原本的严寒，使得资本市场议论纷纷，再 度"火热"起来。 这也代表着，历经378天后，山东药玻的"未央"遗憾，有望得到弥补。 公告称，山东药玻拟以16.25元每股的价格向特定对象中国国际医药卫生有限公司（以下简称"国药国际"）及其关联 方发行股票，募资总额预计32.35亿元。待发行完成后，山东药玻控股股东将变更为国药国际，实际控制人将变更为 国药集团，国务院国资委将成为公司最终实际控制人。 发行完成后，股权分布示意图 协议 早在2024年年底，山东药玻就曾传出过与国药集团的"绯闻"。 进入2025年，新年第一天，山东药玻发布公告坐实了这一传闻。 公告称，山东药玻于2024年12月30日收到公司控股股东鲁中投资《关于山东鲁中投资有限责任公司正在筹划战略重组 暨控股股东可能发生变更的通知》。通知中提到，沂源县人民政府与国药国际正在筹划鲁中投资重组事宜，可能涉及 鲁中投资控股股东变更，从而导致公司间接控股股东变更。 这则"官宣"公告前的山东药玻，风头正盛。 2024年公司实现营业收入51.25亿元，同比增长2.87%；归母净利润9.43亿元， ...

Core Viewpoint - Shandong Luzhong Investment Co., Ltd. holds a 19.50% stake in Shandong Pharmaceutical Glass Co., Ltd., making it the controlling shareholder of the company [1] Group 1: Shareholding and Pledge Information - Luzhong Investment has pledged a total of 64,660,000 shares, which accounts for 9.74% of the company's total share capital and 49.98% of its holdings in the company [1] - The pledged shares are not used as collateral for major asset restructuring performance compensation or for other guarantee purposes [1]

Group 1 - The company Shandong Pharmaceutical Glass announced that it received a stock pledge agreement from Luzhong Investment, involving a pledge of 24.3 million shares [1] - As of the announcement date, Luzhong Investment has pledged a total of 64.66 million shares, which accounts for 9.74% of the company's total share capital and 49.98% of the shares held by Luzhong Investment [1]

证券代码：600529 证券简称：山东药玻 编号：2026-012 山东省药用玻璃股份有限公司 关于控股股东部分股份质押的公告 | 是否为 | 是否 | 是否 | 占其所 | 占公司 | 股东名 | 本次质押股 | 质押到 | 质权 | 质押融资 | 控股股 | 为限 | 补充 | 质押起始日 | 持股份 | 总股本 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 数 | 期日 | 人 | 资金用途 | 东 | 售股 | 质押 | 比例 | 比例 | | | | | | | | | | 用于借款 | 中信 | 给山东鲁 | | | | | | | | | | | | | | | | | 证券 | 科物流有 | 股份 | | | | | | | | | | | | | | | | | 2027年 | 限公司投 | 鲁中 | 2026 | 年 | 1 | 月 | 有限 | 是 | 24,300,000 | 否 | 否 | ...

Group 1 - The company currently does not produce glass bottles for photolithography materials [2] - The expansion and renovation project for the annual production of 560 million pre-filled syringes is expected to be completed by the end of 2025 [2] - Further details will be disclosed in the company's announcement on the Shanghai Stock Exchange regarding the completion of certain fundraising projects [2]

Core Viewpoint - Shandong Pharmaceutical Glass (600529.SH) announced the termination of its original controlling shareholder restructuring and finalized a private placement plan to raise 3.235 billion yuan, with the China National Pharmaceutical Group (Sinopharm) set to become the new controlling shareholder, changing the actual controller from the Yiyuan County Finance Bureau of Shandong Province to the State-owned Assets Supervision and Administration Commission of the State Council [1][5][10] Group 1: Company Overview - Shandong Pharmaceutical Glass was established in 1993 with a registered capital of 664 million yuan and is located in Zibo City, Shandong Province [1] - The company is a leading player in the pharmaceutical glass industry, mastering core processes such as borosilicate molded bottles and borosilicate tubes, with product quality at the forefront [1][5] Group 2: Restructuring and Capital Cooperation - The termination of the restructuring was due to a long-anticipated capital cooperation adjustment involving Shandong Luzhong Investment Co., Ltd. (Luzhong Investment), which was the previous controlling shareholder [3][9] - In June 2025, Sinopharm International and its Hong Kong subsidiary signed an investment cooperation agreement with Luzhong Investment, aiming to acquire 51% of Luzhong Investment's shares to indirectly participate in Shandong Pharmaceutical Glass's operations [3][8] Group 3: Private Placement Details - The company plans to issue shares to specific investors to raise no more than 3.235 billion yuan, with a share price set at 16.25 yuan per share, representing 80% of the average stock price over the previous 20 trading days [4][9] - The issuance will not exceed 19,908,420 shares, accounting for 30% of the company's total share capital before the issuance [4][9] Group 4: New Shareholders and Control Changes - The subscribers for the new shares include Sinopharm International and its affiliate Shandong Yaoxin Health Industry Co., Ltd., with Sinopharm International set to acquire 15,607,300 shares and Shandong Yaoxin 4,307,690 shares [4][10] - Post-issuance, Sinopharm International and Shandong Yaoxin will hold a combined 199 million shares, representing 23.08% of the total share capital, making Sinopharm International the controlling shareholder [4][10] Group 5: Future Directions and Funding Utilization - The net proceeds from the fundraising will be used to supplement working capital, focusing on three main development directions: increasing investment in technological innovation, promoting industrial specialization integration, and leveraging Sinopharm International's global network to accelerate international certification processes [5][10] - This collaboration is expected to enhance the company's overall competitiveness and facilitate its transformation into a technology-driven international enterprise [5][10] Group 6: Financial Performance - For the first three quarters of 2025, Shandong Pharmaceutical Glass reported revenue of 3.401 billion yuan, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 542 million yuan, down 24.7% [6][11] - As of the end of September 2025, the company's total assets amounted to 9.882 billion yuan, with total liabilities of 1.733 billion yuan and total net assets of 8.149 billion yuan [6][11]

Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with the issuance subject to various approvals [1][4][5]. Company Announcements - The company held its 11th Board of Directors' fifth meeting, approving the proposal for a private placement of shares to China International Pharmaceutical Health Co., Ltd. and Shandong Yaoxin Health Industry Co., Ltd. [1][4]. - The issuance will result in China International becoming the controlling shareholder, with the actual controller changing to China National Pharmaceutical Group, ultimately controlled by the State Council's State-owned Assets Supervision and Administration Commission [2][6]. Financial Details - The total market capitalization of Shandong Pharmaceutical Glass is currently 13.996 billion yuan, ranking 22nd in the medical device sector and 1495th in the A-share market [1]. - The company reported that the net proceeds from the previous fundraising amounted to 1.842 billion yuan, which was fully utilized for specific projects, with a remaining balance of approximately 769.76 million yuan for future project construction [3]. Shareholder Changes - The original controlling shareholder, Luzhong Investment, will see its shareholding decrease from 19.50% to 15.00% following the issuance [4][6]. - After the issuance, the combined shareholding of China International and Shandong Yaoxin will be 23.08%, leading to a change in control [2][7]. Compliance and Governance - The company has confirmed that there are no commitments to guarantee returns to the issuance targets, nor any financial assistance provided to them [2]. - The independent directors have stated that the issuance plan complies with legal regulations and does not harm the interests of minority shareholders [5][7].